LICENSE AGREEMENTS - Additional Information (Details) - ActiveSite Pharmaceuticals, Inc. [Member] - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Aug. 04, 2017 |
Jun. 30, 2019 |
Jun. 30, 2018 |
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
| Upfront Payment, Payable | $ 750,000 | ||
| Maximum Amount of Milestone Events | $ 36,000,000 | ||
| First milestone payment due after completion of the preclinical work | $ 1,000,000 | ||
| Royalties percentage | 2.00% | ||
| Minimum [Member] | |||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
| Milestone Payments | $ 1,000,000 | ||
| Maximum [Member] | |||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
| Milestone Payments | $ 10,000,000 | ||
| Total royalty payments | $ 10,000,000 |
| X | ||||||||||
- Definition Represents the first milestone payment due after completion of the preclinical work. No definition available.
|
| X | ||||||||||
- Definition Represents the percentage of royalties. No definition available.
|
| X | ||||||||||
- Definition The maximum amount of milestone event which need to occur for making specific range of milestone payment. No definition available.
|
| X | ||||||||||
- Definition The amount of milestone payments recognized. No definition available.
|
| X | ||||||||||
- Definition The amount payable in advance for use of license agreement. No definition available.
|
| X | ||||||||||
- Definition The amount of cash paid for royalties during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|